These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 22867098)

  • 1. The emerging role of histone lysine demethylases in prostate cancer.
    Crea F; Sun L; Mai A; Chiang YT; Farrar WL; Danesi R; Helgason CD
    Mol Cancer; 2012 Aug; 11():52. PubMed ID: 22867098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
    Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M
    Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone modifications, stem cells and prostate cancer.
    Crea F; Clermont PL; Mai A; Helgason CD
    Curr Pharm Des; 2014; 20(11):1687-97. PubMed ID: 23888964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics.
    Chianese U; Papulino C; Passaro E; Evers TM; Babaei M; Toraldo A; De Marchi T; Niméus E; Carafa V; Nicoletti MM; Del Gaudio N; Iaccarino N; Randazzo A; Rotili D; Mai A; Cappabianca S; Mashaghi A; Ciardiello F; Altucci L; Benedetti R
    Mol Metab; 2022 Oct; 64():101561. PubMed ID: 35944897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role and prospect of lysine-specific demethylases in cancer chemoresistance.
    Song YQ; Yang GJ; Ma DL; Wang W; Leung CH
    Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
    Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
    J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
    Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
    Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.
    Tian X; Zhang S; Liu HM; Zhang YB; Blair CA; Mercola D; Sassone-Corsi P; Zi X
    Curr Cancer Drug Targets; 2013 Jun; 13(5):558-79. PubMed ID: 23713993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine Demethylation in Pathogenesis.
    Cao J; Yan Q
    Adv Exp Med Biol; 2023; 1433():1-14. PubMed ID: 37751133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
    Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
    Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A scintillation proximity assay for histone demethylases.
    Yu W; Eram MS; Hajian T; Szykowska A; Burgess-Brown N; Vedadi M; Brown PJ
    Anal Biochem; 2014 Oct; 463():54-60. PubMed ID: 25010373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing histone demethylase inhibitors in cells: lessons learned.
    Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
    Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone demethylases as a potential cancer therapy (Review).
    Diao W; Zheng J; Li Y; Wang J; Xu S
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35801593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting histone lysine demethylases - progress, challenges, and the future.
    Thinnes CC; England KS; Kawamura A; Chowdhury R; Schofield CJ; Hopkinson RJ
    Biochim Biophys Acta; 2014 Dec; 1839(12):1416-32. PubMed ID: 24859458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation.
    Kang MK; Mehrazarin S; Park NH; Wang CY
    Oral Dis; 2017 Sep; 23(6):709-720. PubMed ID: 27514027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
    Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
    Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
    Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y
    Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication.
    Chakravarty S; Jhelum P; Bhat UA; Rajan WD; Maitra S; Pathak SS; Patel AB; Kumar A
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):152-164. PubMed ID: 27664837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers.
    Dorna D; Paluszczak J
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.
    Wang Z; Patel DJ
    Q Rev Biophys; 2013 Nov; 46(4):349-73. PubMed ID: 23991894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.